Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension
Interventions: Medicaid Expansion; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 19 Years to 64 Years
Enrollment: 1,939,783 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Mood Disorders, Hypertension, Overweight and Obesity, Vascular Stiffness, Sleep, Elevated Blood Pressure
Interventions: Cardiovascular Assessments, Actigraphy, Laboratory assessments, Emotional/ Behavioural assessments; Diagnostic Test · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: Up to 22 Years
Enrollment: 37 participants
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ocular Hypertension
Interventions: Scleral Lens; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: laser trabeculoplasty; Other
Lead sponsor: Santa Clara Valley Health & Hospital System; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Jose, California

Conditions: Glaucoma Open-Angle Primary, Glaucoma, Open Angle Glaucoma, Glaucoma, Open-Angle
Interventions: Mitomycin C; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 20 Years to 85 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Arcadia, California • Fountain Valley, California • Los Angeles, California + 1 more

Conditions: Proteinuria, Hypertension, Type II Diabetes
Interventions: Amiloride, HCTZ; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Glaucoma, Ocular Hypertension
Interventions: BGS goggles; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hypertension, Hormone Disturbance, Adiposity
Interventions: Resistance band exercise intervention, No exercise intervention group; Other
Lead sponsor: Pusan National University; Other
Eligibility: Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Alcohol Misuse, Hypertension, Elevated Cardiovascular Risk
Interventions: Alcohol and CVD Management and Engagement through Telehealth and mHealth (ACME-TM); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Postpartum Hypertension (PPHT)
Interventions: Labetalol, Nifedipine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Kidney Disease, Hypertension
Interventions: Procedure: Regional phenylephrine arterial infusion; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Heart Failure With Reactive Pulmonary Hypertension
Interventions: Sildenafil, Placebo; Drug
Lead sponsor: Maya Guglin; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Pulmonary Hypertension
Interventions: Telaglenastat; Drug
Lead sponsor: Chan, Stephen, MD, PhD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension
Interventions: Aliskiren Hydrochlorothiazide, Ramipril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Beverly Hills, California • Santa Ana, California • Conyers, Georgia + 3 more

Conditions: Ocular Hypertension, Glaucoma
Interventions: latanoprost 0.005%, fixed combination latanoprost-timolol, timolol 0.5%; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 1999
U.S. locations: 53
States / cities: Anaheim, California • Sacramento, California • San Francisco, California + 39 more

Conditions: Hepatic Encephalopathy, Covert Hepatic Encephalopathy, Cirrhosis, Sleep Disturbances and Insomnia
Interventions: Melatonin tablet 3 mg once daily, Thiamine; Dietary Supplement
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: HBP
Interventions: Not listed
Lead sponsor: SAMBIT MONDAL; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Altamonte Springs, Florida

Conditions: Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Interventions: Treprostinil diethanolamine, Standardized meals; Drug · Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Obesity, Overweight, Hypertension, Diabetes Mellitus
Interventions: MOVE OUT, MOVE!; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 3,169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hypertension, High Blood Pressure
Interventions: ADHINCRA Program; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glaucoma, Open-Angle, Hypertension, Ocular
Interventions: NCX 470, Latanoprost 0.005%; Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Preeclampsia, Pregnancy Induced Hypertension
Interventions: Irbesartan; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 50 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type2 Diabetes Mellitus, Hypertension, PreDiabetes, Overweight and Obesity
Interventions: DASH diet, Very low carbohydrate, ketogenic diet, Extras; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 70 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Evaluating Control of Hypertension - Effect of Social Determinants

Association of Mood With Risk for Atherosclerosis

Intraocular Pressure in Ocular Hypertensives With Scleral Lens Wear

Evaluation of Pascal Laser Trabeculoplaty

Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy

Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes

Retinal Effects of Balance Goggles System in Glaucoma Balance Goggles System (BGS) in Patients With Glaucoma

12 Weeks of Resistance Band Exercise Impacts on Adiposity, Hormones, and Blood Pressure in Postmenopausal Women

A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg

Telehealth Treatment of Veterans With Alcohol Misuse at Risk for Cardiovascular Disease

PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy

Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide

Sildenafil in Heart Failure With Reactive Pulmonary Hypertension

TEPH: Telaglenastat Efficacy in Pulmonary Hypertension

Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension

A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

Affect of Melatonin on Sleep and Cognition in Cirrhosis

HIS Bundle Pacing Synchrony Comparing HIS Pacing to Intrinsic Conduction While Using the Medtronic ECG Belt System

Effect of Food on the Pharmacokinetics of Oral Treprostinil

MOVE OUT: A Partnership With Veterans Groups to Enhance Weight Management in the Veterans Health Administration (VHA)

Addressing Hypertension Care in Africa Program

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Preeclampsia: A Marker for Future Cardiovascular Risk in Women

The MHERO Study (Michigan's Hypertension, Diabetes, and Obesity Education Research Online)